Saturday 17 October 2026
Export BDRX’s income statement to Excel — free account
Biodexa Pharmaceuticals PLC Unsponsored ADR
BDRX Healthcare Biotechnology
Biodexa Pharmaceuticals PLC Unsponsored ADR’s revenue for fiscal 2023 (year ended December 2023) was $473,900.00, down 45.2% from fiscal 2022.
0.46
0.03
+6.98%
Follow BDRX
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) P/E ratio
Biodexa Pharmaceuticals PLC Unsponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2023 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR | n/m |
| CDT CDT Equity Inc. compare | n/m |
| VINC Vincerx Pharma, Inc. compare | n/m |
| ATXI Avenue Therapeutics, Inc. compare | n/m |
| LYRA Lyra Therapeutics, Inc. compare | n/m |
| BTTX Better Therapeutics, Inc. compare | n/m |
| SEELQ Seelos Therapeutics, Inc. compare | n/m |
| EFTR eFFECTOR Therapeutics, Inc. compare | n/m |
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)